Nurix Therapeutics Inc. (NRIX) has reported promising results from its ongoing Phase 1a/1b clinical trial of NX-5948, a brain-penetrating oral degrader of Burton's tyrosine kinase (BTK), in patients with relapsed or refractory Waldenström's macroglobulinemia (WM). These findings were shared at the 12th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-12).
The trial results reveal that NX-5948 exhibits significant clinical efficacy, achieving objective responses in seven out of nine evaluable Waldenström's patients (77.8%). Additionally, two patients maintained stable disease (22.2%). The responses were not only significant but also persistent, with two individuals remaining on the therapy for over a year.
Based on these encouraging outcomes, Nurix Therapeutics plans to continue advancing NX-5948 into an expanded Phase 1b cohort. This includes patients who have undergone at least one previous treatment line, including a BTK inhibitor, and those with Bing-Neel syndrome—a rare WM variant with central nervous system involvement. The brain-penetrating capability of NX-5948 could provide a unique therapeutic advantage for these patients.
